Jove
Visualize
Contact Us

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

330
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
330
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

3.0K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
3.0K
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

37
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
37
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

473
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
473
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

2.7K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.7K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.9K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Concizumab in patients with hemophilia A or B without inhibitors: 56-week cut-off results of the phase 3 explorer8 study.

Blood advances·2026
Same author

Nine areas with outstanding challenges for hemophilia B research.

Therapeutic advances in hematology·2026
Same author

Investigation of the Suitability of the ROTEM Assay to Measure Coagulation Potential in Blood From Patients on Concizumab Prophylaxis.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

florio HAEMO-A Digital Medical Device for Monitoring of Treatment, Symptoms and Physical Activities for People Living With Haemophilia.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

Noncarrier mothers of hemophilia A patients with Intron 22 inversions often have other rearrangements.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Evaluation of kidney function and damage in patients with hemophilia B-insights from the B-Natural study.

Research and practice in thrombosis and haemostasis·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Apr 17, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.7K

FVIII inhibitors: pathogenesis and avoidance.

Jan Astermark1

  • 1Department for Hematology and Vascular Medicine, Center for Thrombosis and Haemostasis, Skåne University Hospital, Malmö, Sweden.

Blood
|February 26, 2015
PubMed
Summary

Inhibitory antibodies in hemophilia A result from complex immune responses influenced by genetics and treatment. Understanding these factors is crucial for predicting and preventing antibody formation in patients.

Area of Science:

  • Immunology
  • Hematology
  • Genetics

Background:

  • Inhibitory antibodies are a significant complication in hemophilia A treatment.
  • Their formation is influenced by multiple constitutional and therapy-related factors.
  • Research is challenged by small patient cohorts, risking confounded results.

Purpose of the Study:

  • To review current understanding of immunological mechanisms behind inhibitory antibodies in hemophilia A.
  • To summarize identified risk factors for their development.
  • To discuss implications for clinical management strategies.

Main Methods:

  • Literature review of immunological mechanisms.
  • Analysis of risk factors for antibody formation.
  • Discussion of clinical management based on current evidence.

More Related Videos

Assembly and Purification of Prototype Foamy Virus Intasomes
10:20

Assembly and Purification of Prototype Foamy Virus Intasomes

Published on: March 19, 2018

6.0K
Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

31.0K

Related Experiment Videos

Last Updated: Apr 17, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.7K
Assembly and Purification of Prototype Foamy Virus Intasomes
10:20

Assembly and Purification of Prototype Foamy Virus Intasomes

Published on: March 19, 2018

6.0K
Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

31.0K

Main Results:

  • Decisive factors for immune response are multifactorial, involving genetic and treatment-related components.
  • Small study cohorts pose challenges for reliable data interpretation.
  • Careful data interpretation is essential for informed clinical decisions.

Conclusions:

  • Current concepts of immunological mechanisms and risk factors are summarized.
  • Findings provide a basis for interpreting data and influencing patient management.
  • Further research is needed to overcome cohort size limitations.